Challenges in liver cancer and possible treatment approaches

被引：1278

作者：

Anwanwan, David ^{[1
]}

Singh, Santosh Kumar ^{[1
]}

Singh, Shriti ^{[2
]}

Saikam, Varma ^{[3
]}

Singh, Rajesh ^{[1
]}

机构：

[1] Morehouse Sch Med, Canc Hlth Equ Inst, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA

[2] Banaras Hindu Univ, Inst Med Sci, Dept Kriya Sharir, Varanasi 221005, Uttar Pradesh, India

[3] Georgia State Univ, Ctr Therapeut & Diagnost, Dept Chem, Atlanta, GA 30302 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2020年 / 1873卷 / 01期

关键词：

Liver cancer; Natural compound; Immunotherapy; Chemotherapeutics; ADVANCED HEPATOCELLULAR-CARCINOMA; CNIDIUM-OFFICINALE MAKINO; CELL-CYCLE ARREST; BLACK PEPPER; SORAFENIB; PIPERINE; APOPTOSIS; DIAGNOSIS; CURCUMIN; DELIVERY;

D O I：

10.1016/j.bbcan.2019.188314

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth. Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor prognosis. Of all liver cancer cases, > 90% are hepatocellular carcinomas (HCCs) for which chemotherapy and immunotherapy are the best options for therapy. For liver cancer patients, new treatment options are necessary. Use of natural compounds and/or nanotechnology may provide patients with better outcomes with lower systemic toxicity and fewer side effects. Improved treatments can lead to better prognoses. Finally, in this review, we present some of the problems and current treatment options contributing to the poor outcomes for patients with liver cancer.

引用

页数：7

共 84 条

[1]

[Anonymous], J CLIN ONCOL S4

[2]

[Anonymous], MOL CANC THER

[3] Thymoquinone-based nanotechnology for cancer therapy: promises and challenges [J].

Ballout, Farah ;

Habli, Zeina ;

Rahal, Omar Nasser ;

Fatfat, Maamoun ;

Gali-Muhtasib, Hala .

DRUG DISCOVERY TODAY, 2018, 23 (05) :1089-1098

[4]

Banerjee Saswati, 2017, Front Biosci (Elite Ed), V9, P235

[5] Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 [J].

Bhardwaj, RK ;

Glaeser, H ;

Becquemont, L ;

Klotz, U ;

Gupta, SK ;

Fromm, MF .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02) :645-650

[6] The Role of Inflammation in Liver Cancer [J].

Bishayee, Anupam .

INFLAMMATION AND CANCER, 2014, 816 :401-435

[7] Human T cell responses against melanoma [J].

Boon, Thierry ;

Coulie, Pierre G. ;

Van den Eynde, Benoit J. ;

van der Bruggen, Pierre .

ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :175-208

[8] The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) [J].

Breitbach, Caroline J. ;

Bell, John C. ;

Hwang, Tae-Ho ;

Kirn, David H. ;

Burke, James .

ONCOLYTIC VIROTHERAPY, 2015, 4 :25-31

[9] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial [J].

Bruix, Jordi ;

Raoul, Jean-Luc ;

Sherman, Morris ;

Mazzaferro, Vincenzo ;

Bolondi, Luigi ;

Craxi, Antonio ;

Galle, Peter R. ;

Santoro, Armando ;

Beaugrand, Michel ;

Sangiovanni, Angelo ;

Porta, Camillo ;

Gerken, Guido ;

Marrero, Jorge A. ;

Nadel, Andrea ;

Shan, Michael ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Llovet, Josep M. .

JOURNAL OF HEPATOLOGY, 2012, 57 (04) :821-829

[10] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial [J].

Cainap, Calin ;

Qin, Shukui ;

Huang, Wen-Tsung ;

Chung, Ik Joo ;

Pan, Hongming ;

Cheng, Ying ;

Kudo, Masatoshi ;

Kang, Yoon-Koo ;

Chen, Pei-Jer ;

Toh, Han-Chong ;

Gorbunova, Vera ;

Eskens, Ferry A. L. M. ;

Qian, Jiang ;

McKee, Mark D. ;

Ricker, Justin L. ;

Carlson, Dawn M. ;

El-Nowiem, Saied .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) :172-U77

← 1 2 3 4 5 6 7 8 9 →